Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the European Society of Human Genetics (ESHG) 2022 Conference, with 13 scientific and poster presentations highlighting the application of OGM across rare undiagnosed genetic disease and genetic disorders. Additionally, Bionano and Hamilton will present the Long String VANTAGE, the world’s first automation solution for UHMW extraction used in OGM.
ESHG is an annual conference that brings together industry and academic professionals to discuss new technologies and advances in the field of human genetics. ESHG sessions will take place June 11-14, 2022 virtually and in Vienna, Austria.
Bionano and Hamilton jointly announced the Long String VANTAGE, which is the first Assay Ready Workstation solution in Hamilton´s Long String Genomics product program which supports extraction of UHMW DNA at increased scale. Attendees at ESHG will be able to learn more about the Long String VANTAGE at both companies’ booths and can experience a demonstration of the workflow at Hamilton’s booth throughout the conference.
As part of a corporate satellite presentation, Dr. Detlef Trost from Laboratoire CERBA, and Dr. Alexander Hoischen from Radboud UMC, will share their latest research on OGM for RUGD.
Three genomics researchers will participate in separate featured scientific presentations, highlighting use of OGM in genetic disorder testing. Dr. Claudia Carvalho of the Pacific Northwest Research Institute will present on complex genomic rearrangement structures (CGRs) in neurodevelopmental disorders. Dr. Laïla El Khattabi will present on a recent study highlighting the OGM in the characterization of complex SVs. Dr. Kornelia Neveling from Radboud UMC will present on repeat expansion disorder testing using OGM.
Scientific presentations and poster sessions from Bionano and customers include:
|ACV, Room G, Level-2||See More, Know More: How OGM Provides Answers for Rare Undiagnosed Genetic Disease||Trost D., Hoischen A., Delpu Y.||June 11, 2022|
|Hall E-2, Concurrent Symposia S05||S05.2: Identification of Complex Genomic Rearrangement Structures in Disease||Carvalho C.||June 12, 2022|
|Hall E2-Workshop: What’s New in Cytogenomics?||W12: Optical Genome Mapping Enables Next-Generation Cytogenetics||El Khattabi L.||June 13, 2022|
|Hall E2- Concurrent Sessions C27||C27.3: Optical Genome Mapping for Repeat Expansion Disorder Testing||Neveling K.||June 14, 2022|
|P15.004.A||Structural and copy number variant detection, filtering, annotation, and classification by optical genome mapping in constitutional disorders||Delpu Y.||Poster Session |
June 12, 2022
|P11.010.A||FSHD analysis pipeline by Bionano optical genome mapping: A field report||Heinrich U.||Poster Session |
June 12, 2022
|P13.107.A||An insertion in the MSH2 gene detected by Bionano optical mapping and confirmed by Nanopore sequencing in a family with suspected Lynch Syndrome||Aaløkken R.||Poster Session |
June 12, 2022
|P09.027.C||Optical genome mapping analysis of FMR1 expansions in fragile X syndrome and multi-site validation||Venier A.||Poster Session |
June 13, 2022
|P15.003.D||Comparative benchmarking of optical genome mapping and chromosomal microarray reveals high technological concordance in CNV identification and structural variant refinement||Jaber D.||Poster Session |
June 13, 2022
|P16.020.D||Optical genome mapping in routine human genetic diagnostics: Lessons learned||Dremsek P.||Poster Session |
June 13, 2022
|P16.032.D||Optical Genome Mapping as a diagnostic tool in cases of unresolved rare diseases||Trost D.||Poster Session |
June 13, 2022
|EP15.018||A paracentric inversion that disrupts the SHANK2 gene resolved using cytogenomics||Huyghebaert J.||E-Poster|
|EP15.002||Recurrent constitutional chromosome five inversion revisited||Doco-Fenzy M.||E-Poster|
More details on the conference can be found here.
“We are thrilled to see the broad range of presentations featuring OGM at ESHG this year. These institutions and their research teams have conducted innovative research to help demonstrate the potential utility of OGM as a more sensitive, faster and less expensive alternative to traditional cytogenetics methods,” commented Erik Holmlin, president and chief executive officer of Bionano. “We are also excited for attendees to learn more about our collaboration with Hamilton and the Long String VANTAGE automation system. We believe this innovation can significantly reduce time to results, reduce hands on time and improve OGM performance by standardizing the process of UHMW DNA isolation, and we look forward to sharing more at ESHG.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “potential,” “can,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the potential contribution of our OGM solutions to offer the anticipated benefits for and contributions to the areas reported in the presentations given and posters made available at the ESHG Annual Meeting; anticipated benefits and improvements resulting from the use of Long String VANTAGE to reliably and consistently isolate high quality and sufficient quantity of UHMW DNA for use with OGM . Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; the ability of our OGM solutions to offer the anticipated benefits for and contributions to the areas of research reported in the presentations given and posters made available at the ESHG Annual Meeting; future study results contradicting the results reported in the presentations given and posters made available at the ESHG Annual Meeting; the ability of Long String VANTAGE system to reliably and consistently isolate high quality and sufficient quantity of UHMW DNA for use with OGM; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
+1 (858) 366-3243
|Daily Change:||-0.03 -3.41|
June 08, 2023
June 06, 2023
May 09, 2023
April 26, 2023
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...CLICK TO LEARN MORE